Abstract

In this study we compared nine Shiga toxin (Stx)-producing Escherichia coli O157:H7 patient isolates for Stx levels, stx-phage insertion site(s), and pathogenicity in a streptomycin (Str)-treated mouse model. The strains encoded stx2a, stx1a and stx2a, or stx2a and stx2c. All of the strains elaborated 105-106 cytotoxic doses 50% (CD50) into the supernatant after growth in vitro as measured on Vero cells, and showed variable levels of increased toxin production after growth with sub-inhibitory levels of ciprofloxacin (Cip). The stx2a+stx2c+ isolates were 90–100% lethal for Str-treated BALB/c mice, though one isolate, JH2013, had a delayed time-to-death. The stx2a+ isolate was avirulent. Both an stx2a and a recA deletion mutant of one of the stx2a+stx2c+ strains, JH2010, exhibited at least a three-log decrease in cytotoxicity in vitro and both were avirulent in the mice. Stool from Str-treated mice infected with the highly virulent isolates were 10- to 100-fold more cytotoxic than feces from mice infected with the clinical isolate, JH2012, that made only Stx2a. Taken together these findings demonstrate that the stx2a-phage from JH2010 induces to higher levels in vivo than does the phage from JH2012. The stx1a+stx2a+ clinical isolates were avirulent and neutralization of Stx1 in stool from mice infected with those strains indicated that the toxin produced in vivo was primarily Stx1a. Treatment of mice infected with Stx1a+Stx2a+ isolates with Cip resulted in an increase in Stx2a production in vivo and lethality in the mice. Our data suggest that high levels of Stx2a in stool are predictive of virulence in mice.

Highlights

  • Shiga toxin (Stx)-producing E. coli (STEC) O157:H7 is a foodborne pathogen estimated to cause more than 265,000 episodes of diarrheal illnesses each year in the United States, with more than 3,600 hospitalizations and 30 deaths (Scallan et al, 2011)

  • The finding that the stx2a phage was in argW rather than in wrbA has been shown for 40–77% of human O157:H7 isolates (Shaikh and Tarr, 2003; Shringi et al, 2012)

  • The stx2a+stx2c+ strains did not have stx1, yehV was occupied by an stx1-like defective phage, a finding that has been described for some other STEC (Shaikh and Tarr, 2003)

Read more

Summary

Introduction

Shiga toxin (Stx)-producing E. coli (STEC) O157:H7 is a foodborne pathogen estimated to cause more than 265,000 episodes of diarrheal illnesses each year in the United States, with more than 3,600 hospitalizations and 30 deaths (Scallan et al, 2011). 3–20% of people with confirmed E. coli O157 infection develop hemolytic uremic syndrome (HUS), a sequela characterized by acute kidney failure, thrombocytopenia, and hemolytic anemia. Children are disproportionately affected as over 90% of STEC-associated HUS cases occur among children under the age of 5 (Friedrich et al, 2002; Spinale et al, 2013). The use of antibiotic therapy in patients infected with STEC is linked to an increased risk for the HUS (Freedman et al, 2016). The long-term sequelae of STEC-related HUS in both children and adults can include renal, neurological, pulmonary and cardiac complications (Tarr et al, 2005). The only recommended treatment for STEC-related HUS involves supportive therapy, such as intravenous volume expansion, which has been shown to improve long-term renal outcome (Ake et al, 2005)

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call